Bone marrow transplantation in children. I. Clinical aspects
Kato, S.; Hoshi, N.; Muranaka, S.; Kimura, M.; Nagao, T.; Watanabe, K.; Mori, T.; Tamaoki, N.; Hata, J.; Tsuji, K.
Nihon Ketsueki Gakkai Zasshi Journal of Japan Haematological Society 48(5): 1168-1175
1985
ISSN/ISBN: 0001-5806 PMID: 3907242 Document Number: 249133
Ten children between the ages of five and fifteen years with leukemia (2 ANLL in first remission, 4 ALL in first or second remission, 1 ALL in relapse, 1 CML in chronic phase), malignant lymphoma (1) or severe aplastic anemia (1) were given allogenic bone marrow transplants between March 1982 and January 1984. Nine patients received marrow their HLA-identical siblings, and one received HLA-one-haploptype identical marrow from his father. The cytoreduction regimen with high dose of cyclophosphamide and total body irradiations was well tolerated. Two patients died of leukemia relapse 107 and 257 days following transplant. One patient died of cardiac failure after 157 days. One patient who received HLA-mismatched marrow died of pulmonary edema and acute graft-versus-host disease at 32 days. Six are living 177-752 days following transplantation. None of ten patients have developed interstitial pneumonia due to cytomegalovirus, which was one of the major causes of death in other reports. The results indicate that high-dose chemotherapy and total body irradiation followed by allogeneic bone marrow transplantation can produce complete reconstitution of marrow and long-term remission of hematological malignancies in patients with aplastic anemia, leukemia or malignant lymphoma.